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Abstract: Antimicrobial resistance is now considered a major global challenge; compromising medical
advancements and our ability to treat infectious disease. Increased antimicrobial resistance has
resulted in increased morbidity and mortality due to infectious diseases worldwide. The lack of
discovery of novel compounds from natural products or new classes of antimicrobials, encouraged
us to recycle discontinued antimicrobials that were previously removed from routine use due to
their toxicity, e.g., colistin. Since the discovery of new classes of compounds is extremely expensive
and has very little success, one strategy to overcome this issue could be the application of synthetic
compounds that possess antimicrobial activities. Polymers with innate antimicrobial properties or
that have the ability to be conjugated with other antimicrobial compounds create the possibility
for replacement of antimicrobials either for the direct application as medicine or implanted on
medical devices to control infection. Here, we provide the latest update on research related to
antimicrobial polymers in the context of ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens. We
summarise polymer subgroups: compounds containing natural peptides, halogens, phosphor and
sulfo derivatives and phenol and benzoic derivatives, organometalic polymers, metal nanoparticles
incorporated into polymeric carriers, dendrimers and polymer-based guanidine. We intend to
enhance understanding in the field and promote further work on the development of polymer based
antimicrobial compounds.
Keywords: antimicrobial resistance; antimicrobial polymers; ESKAPE pathogens
1. Introduction
Antimicrobial resistance (AMR) is currently widespread across 22 countries with an estimated
500,000 people infected worldwide [1]. A report by O’Neill and colleagues has estimated 10 million
deaths in 2050 will be due to AMR (Figure 1) [2]. Such data informed and shaped the Global Action Plan
on Antimicrobial Resistance and has encouraged governments and public health agencies to increase
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efforts in AMR surveillance and research. To date, 52 countries (25 high-income, 20 middle-income
and 7 low-income countries) have provided information about their national surveillance systems and
data on levels of AMR [2].
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Figure 1. The estimated number of deaths at every continent in 2050 attributed to antimicrobial
resistance (AMR). Image adapted from [2].
This surveillance and data are important in monitoring and clarifying the epidemiology of AMR,
in order to allow priorities to be set and to develop public health policy and strategies targeting
this global concern. In this first section of the review, we provide the current epidemiology of
multidrug-resistant organisms (MDROs) globally, focusing mainly on ESKAPE pathogens (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter spp.). These ESKAPE pathogens are capable of “escaping” from common antibacterial
treatments and have been listed as World Health Organization (WHO) priority pathogens with
critical and high priority [3]. Although extensive studies on the prevalence of antimicrobial resistance
pathogens were conducted, these studies were largely limited to certain countries and we believe
that these data are not able to showcase the overall picture of antimicrobial resistance around the
globe. Hence, we sought to evaluate the current global prevalence of ESKAPE pathogens by reviewing
published work performed between the years 2013–2018 (Table 1).
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Table 1. The global prevalence of AMR among ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter spp.) pathogens.
Country
Pathogens Enterococcus
faecium
Staphylococcus
aureus
Klebsiella
pneumoniae
Acinetobacter
baumannii
Pseudomonas
aeruginosa Enterobacter spp. References
Thailand - - ER ER - - [4]
South India - - - - S - [5]
India ER ER ER ER ER ER [6]
India
(Veterinary Cases) ER ER ER ER ER ER [7]
Iran ER HR R ER ER HR [14]
Asia-Pacific - - R ER S S [8]
Southern Italy S R S ER R - [9]
Romania HR R HR HR HR - [10]
Romania H ER ER ER S - [11]
South Africa R S ER H S - [12]
Brazil ER ER HR HR ER ER [13]
Latin-America - - R ER S S [8]
- (N/A) = data on the AMR prevalence are not available in the study, S (Susceptible) = 50% of the organism does not show resistance against any antibacterial agent; R (Resistant) = 50% of
the organism must show resistance against an antibacterial agent from 1 of the antibiotic groups; HR (Highly Resistant) = 50% of the organism must show resistance against antibacterial
agents from at least 2 of the antibiotic groups; ER (Extremely Resistant) = 50% of the organism must show resistance against antibacterial agents from at least 3 of the antibiotic groups.
Antibiotic groups: Aminoglycosides, Carnapenems, Cephalosporins, Glycopeptides, Lincosamides, Lipopeptide, Macrolides, Monobactams, Nitrofurans, Penicillin, Fluoroquinolones,
Sulfonamides, Tetracycline.
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The claim on the global prevalence status of AMR among ESKAPE pathogens is rather challenging
as standardisation of resistance testing across antibiotic groups being employed by the available studies
is lacking. In order to give a simple visualization on the current global prevalence of antimicrobial
resistance among ESKAPE pathogens, we compiled a meta-analysis of works conducted in different
geographical locations and classified them into 4 major classes namely, susceptible, resistant; highly
resistant and extremely resistant by having 50% of the organism show resistance against none, one or
more of the 13 antibiotic groups stated.
According to the summarized work in Table 1, A. baumannii is reported as extremely resistant
i.e., 50% resistant to at least 3 drug classes for all selected countries. It is considered one of the most
challenging ESKAPE pathogens due to its particular antimicrobial resistance characteristics, having
developed resistance to almost all known antimicrobials [14]. The increasing trend of multidrug
resistant (MDR) pathogens has diminished the options of effective therapeutic drugs for bacterial
infection. The return to the previously abandoned antimicrobial, colistin, considered to be the ‘last
resort’ treatment is also challenging as emerging resistant clinical isolates to colistin has been reported
globally [15,16].
Limiting overuse and misuse of antimicrobials were proposed as the solution to limit and even
reduce the MDR pathogens. However, the theory of reduction in resistance in the absence of a given
antimicrobial is no longer a novel approach [17]. Although theoretically attractive, the reversibility of
resistance has proven difficult in practice as the success rate is highly dependent on many other factors
such as the fitness cost of the resistance mechanism, the epidemic potential of the bacteria/strain, and
the transmission route of the species [18]. Efforts to develop new antimicrobials concurrently have
diminished due to a combination of market forces and the inability to match the fast-paced growth of
antimicrobial resistance in superbugs [19].
Decisively, although antimicrobial resistance does not seem obviously reversible, efforts must still
be focused on imposing measures that might postpone the increase in antimicrobial resistance. The
overall use of antimicrobials must be reduced. The prudent use of antimicrobials should always be
promoted. Alternative and preventive measures (such as vaccination) that can ultimately replace the
use of antimicrobials should always be explored ahead of administration of antimicrobials.
2. ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) pathogens
The acronym ESKAPE paradoxically denotes the ability of the panel of constituent bacteria, namely
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter spp., to escape the antimicrobial activities of most commonly used products
in clinical treatment. The AMR capabilities of this bacterial group have been reported to severely
exacerbate the condition of hospitalised patients with noncommunicable diseases, such as diabetes,
cancer, cardiovascular diseases, and chronic respiratory diseases; breakage of skin barrier such as
wounds; and diseases that lead to immunosuppression [4]. Exposure of these patients to ESKAPE
pathogens could occur during hospitalisation through contact with medical equipment (commonly
related to central line bloodstream infections, ventilator pneumonia, and urinary catheterisation), other
infected patients, and healthcare staff. WHO has recently published a list of bacteria that urgently
require new antibiotics and ESKAPE bacteria were identified among Priority 1 and 2 lists; as these are
multidrug resistant microorganisms that pose serious threats in healthcare facilities [20].
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2.1. Enterococcus faecium
Enterococci are gram-positive, facultative anaerobic organisms that form part of the normal
intestinal flora. Among the 17 species of Enterococci, Enterococcus faecium and E. faecalis were most
frequently reported to be pathogenic in humans. The pathogenic strains of these organisms cause
a variety of infections, involving the endocardium, urinary tract, prostate, intra-abdominal organs,
skin (particularly if present within a wound) [5]. If bacteria enter the normally sterile bloodstream
through parenteral injections, catheterisation, surgery and open wounds, this can result in metastatic
or systemic infections that eventually result in sepsis and septic shock. Research has shown that
various virulence factors are present on the capsule, cell wall, membrane and within the cytoplasm of
Enterococcus faecium that contributed to AMR and pathogenicity of the organism through formation of
a protective and persistent biofilm, ß-lactamase production, and proteins directed against recruited
inflammatory cells [6,7]. Reports submitted to the National Healthcare Safety Network (NHSN) at
the Centres for Disease Control and Prevention (CDC) indicated that the Enterococcus group is the
second most common pathogen across all hospital-acquired infections types (HAI) types. While
Enterococcus faecium was ranked among the top ten organisms across all types of HAI, including central
line-associated bloodstream infection (CLABSI), catheter-associated urinary tract infection (CAUTI),
and surgical site infections (SSIs) [21].
2.2. Staphylococcus aureus
Staphylococcus aureus is a Gram-positive coccus that is frequently isolated from the skin, respiratory
tract, and female lower reproductive tract as it forms part of the normal flora on the human body [8,9].
S. aureus infection has shown increased resistance towards penicillin, which led to the introduction
of methicillin for the treatment of S. aureus showing resistance to penicillin in 1960 [10]. However,
S. aureus developed resistance towards methicillin, thus giving rise to methicillin-resistant S. aureus
(MRSA) clones [11]. MRSA is the second most common cause of HAI in the USA according to a
report from the CDC [12]. The ability of the organism to form biofilms on tissues such as the skin
and inert indwelling device surfaces such as intravenous catheters and surgical implants, further
exposes susceptible individuals as the most common route of MRSA transmission is through direct
contact [13]. Additionally, S. aureus can invade host cells and evade the antimicrobial effects of
administered therapies [20,22]. Successful treatment of MRSA infection is restricted by worldwide
antibiotic resistance towards first-line therapies such as vancomycin and teicoplanin [13]. Together,
these characteristics allow this microorganism to remain an important pathogen and alternative
therapeutic measures are critically needed.
2.3. Pseudomonas aeruginosa
P. aeruginosa is a Gram-negative, rod-shaped, facultative anaerobe that is ubiquitous in the
environment and forms part of the normal gut flora. P. aeruginosa is capable of forming biofilms on
medical device surfaces, thus patients dependent on breathing machines or fitted with an invasive
device such as a catheter are at risk of severe and life-threatening illness [23–25]. Reported illnesses
include endocardial valve infection through endocardial tubes, ventilator-associated pneumonia (VAP)
and CAUTI. Additionally, P. aeruginosa has also been reported to be able to grow in intravenous fluid
and could enter the bloodstream and cause sepsis [26–28]. The emergence of extremely drug-resistant
(XDR) P. aeruginosa towards multiple antibiotics, e.g., cephalosporins and carbapenems, increases the
problem of treatment globally and clinicians need to resort to the last available medication, colistin, a
polymyxin antibiotic which was avoided for the past thirty years as it has been implicated in both
neuro- and nephrotoxicity [29–32].
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2.4. Klebsiella pneumoniae
K. pneumoniae is a non-fastidious, Gram-negative bacillus and commonly encapsulated. Although
K. pneumoniae is among the population of normal flora found in the mouth, skin, and intestine, it
has been reported to cause infections in the lungs, urinary tract, and bloodstreams of patients from
hospitals, nursing homes and other healthcare facilities [30]. This bacterium is a remarkably resilient
pathogen, instead of actively suppressing many components of the immune system, it successfully
evades the body’s defence mechanisms and survives in the most harsh environments. This organism
can survive and grow within the intravenous fluid and form biofilm on medical devices such as
the urinary catheter, leading to detrimental septicaemia in patients [33]. Furthermore, the bacteria
have developed resistance towards almost all available antibiotics: fluoroquinolones, third-generation
cephalosporins and aminoglycosides [34]. The emergence of the carbapenem-resistant K. pnemoniae
strains circulating across the globe has forced the administration of colistin, an old antibiotic and
considered the last available. Nevertheless, resistance towards colistin was recently reported, rendering
treatment of multidrug resistant K. pneumoniae even more difficult [35].
2.5. Acinetobacter baumnannii
Acinetobacter baumnannii is a Gram-negative coccobacillus, of unknown natural habitat, that
causes nosocomial infections in immunocompromised patients, including bacteraemia, pneumonia,
meningitis, urinary tract infection, and wound infection [36]. The Acinetobacter species have a great
capacity of extensive antimicrobial resistance resulting from its relatively impermeable outer membrane,
the presence of efflux pumps, and lack of protein channels. Additionally, the bacteria produce various
enzymes, such as beta-lactamases, to render multiple antibiotics ineffective; persistent adherence to
surface through biofilm formation; as well as insertion of resistance genes from other bacterial species
through genomic mutation [37]. Over the past three decades, A. baumnannii has been reported to be
resistant to most known antibiotics, even in some cases towards colistin, the last resort of antibiotics in
human medicine albeit with adverse side effects [38–40]. A combination of antibiotic treatment using
colistin methansulfonate (CMS), a carbapenem, and ampicillin-sulbactam was reported to have the
highest rate of success for colistin-resistant A. baumnannii [40]. The source of infection could originate
from numerous sites and medical equipment within the healthcare facilities, including the door handle,
curtains, keyboard, etc. However, the most detrimental effects involve patients infected through
treatment involving the use of ventilator and venipuncture catheterisation where the mortality rates
can reach 35% [41,42].
2.6. Enterobacter spp.
Enterobacter is a genus of Gram-negative bacilli from the family Enterobacteriaceae. These bacteria
are facultative anaerobes that do not form spores but may be encapsulated. Two of the most clinically
relevant species are Enterobacter aerogenes, and Enterobacter cloacae [43]. The worldwide emergence of
colistin resistance genes (mcr-1, -2, -3, -4, -5, -6, -7, and the latest -8) in Enterobacteriaceae bacteria has
detrimentally threatened global health as this polymyxin compound is considered the last resort of
treatment [44]. According to the report provided by Weiner et al., Enterobacter spp. are among the top
10 pathogens detected in CAUTI, CLABSI, SSI and VAP, accounting for 17,235 HAI incidence recorded
at NHSN [45]. In the same report, Enterobacter spp. were found to be resistant to extended-spectrum
cephalosporin (ESC4, i.e., cefepime, cefotaxime, ceftazidime, ceftriaxone); carbapenems (imipenem,
meropenem, doripenem); and multidrug-resistance (MDR1) at 12.8 to 38.2%, 1.9 to 6.6%, and 2.9 to
10.2% respectively [21]. On another note, unchecked antimicrobial misuse in the livestock industry
may exacerbate colistin resistance in the general population as the medication has been added in feed
as a growth promoter, or for treatment and prevention of infectious diseases in many countries.
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3. The Progress in Antimicrobial Development
The development of a new antimicrobial is a lengthy and expensive process. The big
pharmaceutical companies were once the major drivers in antimicrobial discoveries, are now no
longer stand at the forefront of the arena [46]. Beginning in the late 1990s, due to lack of success,
low financial returns and emergence of antimicrobial resistance, these companies began to withdraw
antimicrobial discovery and development from their portfolio, with the final company Novartis
followed suit in July 2018 [47]. Therefore, the task for novel discovery of antimicrobials is now left to
university laboratories and small and medium-sized companies [46]. Only recently, German Ministry
of Education and Research has showed interest to provide funds to Global Antibiotic Research and
Development Partnership (GARDP) to accelerate discovery, development and delivery of affordable
antibiotics to treat Gram-negative infections [48]. Understanding that the discovery of a novel
compounds is a lengthy and expensive process, utilising the current knowledge and compounds would
be one approach to ensure the continuous development of antimicrobials.
4. Antimicrobial Polymers Are the New Generation of Antimicrobials
Continuous research and understanding in the field of chemistry has opened up the possibility
to design and synthesise a compound that has antibacterial activities. A new kind of antimicrobial
must not only be effective against bacteria, but it must also resist the possible development of bacterial
resistance. Antimicrobial polymers (AMP) are materials that have the ability to inhibit or kill the
bacteria. AMP can either display the antibacterial activities through its own inherent chemical structure;
e.g., quaternary nitrogen groups, halamines and poly lysine or it can serve as a backbone to improve
the potency of existing antibiotics [49]. AMPs were designed based on the chemical templates provided
by the antimicrobial peptides, a class of peptides of the innate immune system which protects the
body from invading pathogens (Figure 2) [50]. Antimicrobial peptides (APs) are relatively small in
size (10–50 amino acids), amphiphilic with cationic charge. With these physical characteristics, APs
accumulate on the cell membranes and form pores on the structure, thus killing the bacteria [51].
With multimodal mechanisms of action, APs can resist acquired resistance by the bacteria. For a
detailed understanding of the mechanism of action of APs, readers are invited to refer to the following
article [52]. The structural and chemical diversity allow for polymer chemists to design, manipulate
and construct a variety of polymers with cationic and amphiphilic structures that can function as
antimicrobials. In this review, we have selected a few antimicrobial polymers that have been designed
and tested against multidrug-resistant pathogens.
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4.1. Amphiphilic Antibacterial Polymers
Advancement in natural/synthetic antimicrobial polymers exploratory has also expanded
researchers’ interests in other amphiphilic polymers structures that conferred with antimicrobial
activity [53]. Polymer structures and physicochemical properties such as molecular weight, polymer
architecture, ratio of amphiphilic and its molecular arrangement are the potential determinants of
materials’ antimicrobial potency and selectivity [54]. An ideal amphiphilic antibacterial polymer
harboring a cationic arm, low molecular weight and low-level lipophilicity would likely to incur
adequate antibacterial activity against Gram-positive bacteria and has minimum hemolysis activity
toward human red blood cells i.e., <4% hemolysis at a given minimum inhibitory concentration
(MIC) [55]. Nonetheless, Locock et al., 2014 suggested that the combinational effect offered by the
specific pendant functional groups may alter the potency, selectivity and mechanisms of synthetic
AMP polymers. Some empirical data showed that optimization of the degree of hydrophobicity
and cationic charge is crucial for a amphiphilic polymers to attain the best antibacterial activity
and minimum red blood cells haemolysis [56]. For instance, AMP-mimicking polyurethanes with a
lower ratio of hydrophobic region and higher cationic strength conferred the polymers with higher
bactericidal activity and lower haemolysis rate [57]. In the comparison of cationic amine- and
guanidine-copolymers, the latter of low to moderate molecular weight and hydrophobicity showed
higher antimicrobial activity against S. epidermis and lower toxicity toward red blood cells [55]. On the
other hand, auto-degradation or biodegradation of polymers is an essential consideration in choosing
the right antimicrobial materials [54,58]. Degradable properties of antimicrobial material avoid or
minimize undesired complication caused by prolonged retention of the materials in human body
or towards the environment. Controlled degradation rate of the polymers by tuning of monomer
composition and amine functionality could enhance precise control of the lifespan of antimicrobial
activity [47,59]. Table 2 presents a variety of amphiphilic polymers synthesized by a random synthesis
approach was tested against ESKAPE pathogens.
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Table 2. Amphiphilic antimicrobial polymers activities against ESKAPE pathogens.
Polymers Class Description
Susceptibility Haemolytic
Activity ReferencesE S K A P E
4-aminobutylene side
chain coupled with
hydrophobic
ethylmethacrylate in a
roughly 70/30 ratio
Amphiphilic
Methacrylate
Copolymers
Cationic amphiphilic random
copolymers with ethyl
methacrylate (EMA) comonomer
were prepared with a range of
comonomer fractions, and the
library of copolymers was
screened for antimicrobial and
hemolytic activities.
BC BS - BS BS BS Low [60]
PDMAEMA-g-rosin Cationic polymers
Quaternary ammonium-containing
poly(N,N-dimethylaminoethyl
methacrylate) with natural rosin as
the pendant group.
BS BS - - - - NA [61]
Methacrylate
Copolymer (E429)
Methacrylate
Copolymer
Amphiphilic random copolymers
with modulated cationic side chain
spacer arms structure which
include 2-aminoethylene,
4-aminobutylene, and
6-aminohexylene groups.
BS BS - BS BS BS NA [62]
PAPMA
Amphiphilic
Methacrylamide
Copolymers
A series of copolymers containing
lysine mimicking aminopropyl
methacrylamide (APMA) and
arginine mimicking
guanadinopropyl
methacrylamide (GPMA).
BS BS - - BS - NA [63]
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Table 2. Cont.
Polymers Class Description
Susceptibility Haemolytic
Activity ReferencesE S K A P E
Cationic
polyester-based
copolymer
Self-Degradable
Antibacterial
Polymers
Auto-degradable antimicrobial
copolymers bearing cationic side
chains and main-chain ester
linkages synthesized using the
simultaneous chain- and
step-growth radical
polymerization of t-butyl acrylate
and 3-butenyl 2-chloropropionate,
followed by the transformation of
t-butyl groups into primary
ammonium salts.
BS - - - - - Low-Moderate [58]
AMP-mimicking
polyurethanes
Peptidomimetic
Polyurethanes
Peptidomimetic polyurethanes
with pendant functional groups
that mimic lysine and valine amino
acid residues
BC - - - - - Low [57]
Block Amphiphilic
Copolymers
Amphiphilic
copolymers of
Poly(Vinyl Ether)s
A series of amphiphilic block
copolymers of poly(vinyl ether)
derivatives prepared by
base-assisting living cationic
polymerization.
BS - - - - - Low [64]
Random Amphiphilic
Copolymers
Amphiphilic
copolymers of
Poly(Vinyl Ether)s
A series of amphiphilic random
copolymers of poly(vinyl ether)
derivatives prepared by
base-assisting living cationic
polymerization.
BS - - - - - High [64]
Note: ESKAPE—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.; antibacterial effect: BC—Bactericidal,
BS—Bacteriostatic. Colour code for toxicity: White—data not available, Yellow—low haemolytic activity, Red—high haemolytic activity.
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4.2. Polymers Containing Natural Peptides
APs are produced by living hosts as part of innate immune responses. These protective biologics
are relatively rich at various sites such as epithelial layers, phagocytic cells and body fluids such as
tears and sweat [65,66]. For instance, the major epidermal APs are reported to include cathelicidins
and defensins, which exhibit broad spectrum antimicrobial activities against bacterial, fungal and
viral infections [67]. The mechanism of action is non-receptor dependent; and commonly activated by
the alteration of bacterial membrane structure or enveloped-components, although the interruption
of internal cellular function has gained increasing evidence as illustrated in Figure 3 [68,69]. In
addition, APs confer a higher affinity towards negatively charge bacterial cell membranes compared to
mammalian cell membranes increasing their selectivity [70,71]. However, the clinical implementation of
APs are at the early stages of translation due to the following reasons: (a) susceptibility to degradation
by host proteases (b) potential toxicity to the host due to high concentration needed for antimicrobial
activity and (c) short half-life due to protein binding [72]. Thus, these limitations encourage the
development of synthetic AMP mimics as an alternative approach.
Current studies on synthetic antimicrobial peptides focus on the compound’s susceptibility
to pathogens and its toxicity effect towards the host. The susceptibility towards the pathogen is
determined by the minimum inhibitory concentration of the compound that leads to either 50% (MIC50)
or 90% (MIC90) bacterial growth, wherein the presence of activity was determined if the MIC50 or
MIC90 was less than 100 µg/mL. Compound toxicity towards the host is determined by erythrocytosis
activity. The degree of haemolytic activity of erythrocytes at MIC50 or the compound concentration
leading to 50% red blood cell lysis determines the degree of the toxicity [70].
Selected studies of synthetic antimicrobial peptides and its mimics on ESKAPE pathogens are
highlighted in Table 3. The model ESKAPE species were S. aureus and P. aeruginosa, as the selected
Gram-positive and Gram-negative organisms, respectively. The studies showed bactericidal and/or
bacteriostatic outcomes. Out of many reported compounds, only selected AMPs such as Brilacidin
(also known as PMX-30063), an arylamide-peptide, has been tested in Phase II clinical trials. According
to the fact sheet, a good prognosis in topical treatment of MRSA-infected wound and minimal side
effects were reported [73]. Another AMP mimic, LTX 109, a membrane disrupting compound targeting
Gram-positive and Gram-negative bacteria is currently under phase II clinical trials for the treatment
of impetigo [73]. These two AMPs were indicated for topical used only, owing to the uncertainty from
the aforementioned AMP limitations.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  12 of 35 
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Table 3. Synthetic antimicrobial polymers mimicking peptides activities against ESKAPE pathogens.
Polymers Class Description
Susceptibility Haemolytic
Activity ReferencesE S K A P E
Idolidicin variants Peptide
A 13-residue cationic antimicrobial peptide
(sequence carboxy-terminal amidated
ILPWKWPWWPWRR-NH2)
BC High [66,73]
Gratisin analogues Peptide cyclo(-Val1-Orn2-Leu3-d-Phe4-Pro5-d-Tyr6-)2 BS BS Low [69]
LL-37 Peptide A cathelin-associated antimicrobial peptide BS BS None [74]
α/β-Peptides Peptide
Helix-forming α/β-peptides, i.e., oligomers
containing a 1:1 pattern of α- and β- amino
acid residues in the backbone
BS BS None [75]
cecropin/melittin Peptide Hybrid peptide produced by recombinantDNA technology in S. aureus BC NA [76]
Maleic anhydride
copolymers Peptide mimics
Peptides Mimicking Copolymers of Maleic
Anhydride and 4-Methyl-1-pentene None None High [77]
Brilacidin Peptide mimics
also known as PMX-30063, a
defensin-mimetic and a membrane-targeting
arylamide oligomer
BC NA [71]
cecropin/melittin Synthetic peptide Recombinant hybrid peptide BC NA [76]
LL-37LTX 109 Peptide mimics
a synthetic antimicrobial peptidomimetic
containing a modified tryptophan derivate as
lipophilic bulk, displayed a combination of
high antibacterial activity against MRSA and
Staphylococcus spp. biofilm
BC BS Low [78]
poly(m-phenylene
ethynylene)s Peptide mimics Nonhemolytic abiogenic polymers BS BS BS BS BS BS Low [79]
Pandinin 2 Peptide Variants A scorpion venom AMP contains a centralproline residue BC High [80]
Pyridinium
Functionalized
Polynorbornenes
Synthetic peptide
Amphiphilic polyoxanorbornene with
different quaternary alkyl pyridinium
side-chains
BS NA [81]
Amino-Functionalized
Poly(norbornene) Synthetic peptide
Homopolymers of the amine bearing
monomers and random copolymers of amine-
and alkyl-substituted monomers of high
average molar mass was produced by
ring-opening metathesis polymerization.
BS BS None [82]
Note: ESKAPE—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.; antibacterial effect: BC—Bactericidal,
BS—Bacteriostatic. Colour code for toxicity: White—data not available, Green—No haemolytic activity detected, Yellow—low haemolytic activity, Red—High haemolytic activity.
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4.3. Halogen-Containing Polymers
Halogen (fluorine, chlorine, bromine, iodine) containing polymers with antimicrobial properties
are attractive materials based on unique properties afforded by the associated halogen (Figure 4).
Halogen-containing antimicrobials are well described. Several antimicrobials produced by Streptomyces
spp. contain chlorine; chloramphenicol, chlortetracycline and vancomycin. Fluoroquinolones, effective
against Gram-positive and Gram-negative organisms, are a class of antimicrobials where fluorine is
incorporated within the quinolone structure [83].
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Polymers containing fluorine offer antimicrobial activity due to their hydrophobic nature. A
review by Munoz-Bonilla et al. highlights the use of such polymers, including the creation of a
polymeric fluorine containing surfactant known as Quaterfluo® [67]. The surfactant subunit alone
showed robust antimicrobial activity against P. aeruginosa, S. aureus, C. albicans and A. niger [74]. When
formed as a polymer, the activity against S. aureus increased with the length of the active perfluorakyl
chains [74]. Recently, cationic fluorinated polymer emulsions have been used to create antibacterial
fabrics where the presence of fluorine greatly enhanced both the antibacterial and anti-adhesion
properties of the material when tested against E. coli and S. aureus [75].
Fluorinated polymers containing antimicrobials such as ciprofloxacin, a second-generation
fluoroquinolone, have been investigated to improve solubility and bioavailability. Mesallati and
colleagues prepared amorphous solid dispersions (ASDs) of ciprofloxacin with acidic polymers such
as Eudragit L100, Carbopol and hydroxy propyl methyl cellulose acetate succinate (HPMCAS) [76].
When incorporated in the polymer matrix, the solubility of ciprofloxacin was improved both in water
and in simulated intestinal fluid. When tested against E. coli, S. aureus, P. aeruginosa and K. pneumoniae,
formulations with HPMCAS drastically improved MIC and MBC concentrations as compared to
monomeric ciprofloxacin [76]. Conjugation of ciprofloxacin with polymers have also been used to
create biomedical nanomaterials for use in wound dressings [77]. Ciprofloxacin-PLA (poly l-lactic acid)
conjugated polymers increased the solubility of ciprofloxacin for use in the fabrication of biodegradable
non-woven nanofibers by electrospinning. ciprofloxacin released from the PLA non-woven nanofibers
was effective at inhibiting the growth of E. coli and S. aureus indicating the utility of ciprofloxacin
conjugated polymers as an antimicrobial biomedical material [77].
An effective antimicrobial group of polymers contain N-halamines, in which at least one
nitrogen-halogen covalent bond is formed by the chlorination of imide, amide and amine
groups. A new N-halamine, hydantoin acrylamide (HA), copolymerised with siloxane (SL)
to create PHASL, was used to coat cotton fabric which was shown to be effective against
E. coli O157: H7 and S. aureus within 5 min once activated by chlorination [78]. More
recently the halogenated 2,2,5,5-tetramethyl-1,3-imidazolidinone (TMIO) by chlorination to form
1-chloro-2,2,5,5-tetramethyl-4-imidazolidinone (MC) was found to be effective in reducing bacterial
colony-forming units (CFU) of both S. aureus and P. aeruginosa when coated on wound dressings.
Bactericidal activity was observed in 15 min for S. aureus (6-log reduction) and within 30 min for
Int. J. Mol. Sci. 2019, 20, 2747 14 of 31
P. aeruginosa (7-log reduction) [79]. In this form, MC was also found to be stable when stored in the
dark for 6 months, highlighting an additional utility of N-halamine-coated medical materials designed
for wound dressings.
4.4. Polymers Containing Phosphor and Sulfo Derivatives
Polyphosphonium and polysulfonium are phospo- and sulfo- containing polymers, respectively
(Figure 5). They share their mode of action with polymers comprising quaternary ammonium in
causing damage to the bacterial cell wall. Phosphonium containing polycationic agents are typically
considered to be more microbicidal than quaternary ammonium salt polymers with their antimicrobial
potency positively related to the number of phosphonium units within the polymer [67]. Until recently,
polyphosphoniums studies have been restricted to alkyl and aryl derivatives with the polymers
exhibiting both hydrophobic and hydrophilic domains—a feature considered to be required for
antimicrobial activity. Cuthbert and colleagues unexpectedly discovered that control polymers lacking
hydrophobic alkyl chains exhibit high antimicrobial activity against E. coli and S. aureus while at the
same time low lytic action on erythrocytes [80]. These findings were uncovered when investigating the
ability of ‘baited’ phosphonium polymers to exert increased microbicidal effects, taking advantage of
bacterial affinity to mannose sugars [80]. This work challenges the assumed requirement for balanced
hydrophilic and lipophilic components within biocidal polymers and warrants further investigation
into this promising class of antimicrobial polymers.
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4.5. Phenol and Benzoic Derivative Polymers
Polymers containing the organic and aromatic compounds such as phenol and benzoic acid have
intrinsic antimicrobial prop rties (Figure 6). Phenol is a strong antimicrobial agent able to disrupt
the cellul r membrane, while benzoic acid has br ad spectrum inhibit ry activity and is used as an
environmentally safe antimicrobial. Vinyl polymers containing phenol r benzoic acid pendant groups
were synthesised by Park and colle gues and tested for activity against S. aureus a d P. aeruginosa [81].
While the polymers exhibited lower antimicrobial ctivity than the monomer when test d by halo
diffusion, they have been used as coating materials. Nevertheless, phenol pe dant vinyl polymers
were marginally more effective against S. aureus than P. aeruginosa while the converse was observe for
be zoic acid pendant vinyl poly ers [81]. In contrast, aminated polyacrylo itrile (PAN) polymers
here benzaldehyde derivatives were immobilized via their amine-terminal, were f und to exhibit
increased antimicrobial activity with additional bioactive groups [82]. Inhibitio zone diameters
significantly increased with the num er of bioactive groups in each prepared polymer for several
microbes, including E. coli, P aeruginosa, S. aureus and A. niger [81].
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4.6. Organometallic Polymers
Organometallic polymers contain metals bonded to at least one organic molecule carbon by
pi-bonds, by coordination bonds or by sigma-/pi-bonds to other elements. Antimicrobial formulations
of organometallic polymers are extensive and are reviewed in depth in [67]. Silver-containing polymers
are prevalent, having potent antimicrobial activity in solid form across a wide range of organisms
including key ESKAPE organisms; E. coli, S. aureus, P. aeruginosa and A. niger. The same polymers
in aqueous solutions, howev r, showed reduced efficacy in Gram-positiv bacteria and yeasts [67].
Recently, Awad and colleagues took a novel approach by creating Eco-friendly silver-polystyrene
nanocomposite using touline extracted orange peel to reduce silver nitrate to silver nanoparticles
(AgNP) before creating a polymer with polystyrene. Antibacterial activity was observed by disk
diffusion against E. coli, K. pneumoniae and S. aureus for both AgNP and AgNP/polystyrene polymers,
although reduced for the latter in comparison [83]. Creating AgNP via this simple method, requires
further investigation in the quest for novel, environmentally sound biomaterials. In general, those
polymeric resins containing Cu(II), in comparison to other metal ions, show enhanced antimicrobial
activity against a range of microorganisms which has been attributed to the stability of the Cu(II)
ion [67].
4.7. Metal Nanoparticles Included in Polymeric Carriers
4.7.1. Polymeric Systems Containing Silver Nanoparticles
Silver nanoparticles (AgNPs) alone have a well-established use in the treatment of bacterial
infections. AgNPs show an efficient antimicrobial property due to their extremely large surface area,
which provides better contact with microorganisms [84]. Wen-Ru et al. have studied the antibacterial
activity and acting mechanism of AgNPs on E. coli [85,86]. The authors investigated the growth,
permeability, and morphology f the bacterial cell wall following the treatment with AgNPs. Their
results showed that, based on transmission electron microscopy (TEM) imaging, the bacteria membrane
vesicles were dissolved and dispersed, and the membrane components became disorganized and
scattered from their original ordered and close arrangement [87]. These observations suggested that
AgNPs may damage the structure of the bacterial cell membrane and depress the activity of some
membranous enzymes. Studies have also shown that AgNPs are able to interact with sulfur-containing
proteins present in the bacterial membrane, in the same way as they can interact with phosphorus
groups present i he cell DNA [88]. AgNPs eem to preferably attack the respiratory chain, and
cell division.
The use of AgNPs in biomedical applications has been extended by the incorporation of AgNPs
into polymeric systems forming multilayer films, polymeric nanotubes and nanofibres, and polymeric
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gels. The development of organic−inorganic hybrid nanomaterials has allowed the combination of the
tunable properties of soft nanomaterials with the unique optical and electronic properties of metal
nanoparticles. Due to their tunable surface, morphology and porosity, soft organic materials such as
polymers that are derived from various synthetic or natural compounds can easily incorporate metal
nanoparticles of different shapes and sizes. A large number of polymers have been investigated for
this purpose. AgNPs can be synthesized in situ using the polymer matrix as a reaction medium, or
alternatively, the AgNPs are prepared ex situ and then incorporated into the polymeric matrix [89–91].
Numerous studies have been carried out using different polymer systems [91–94].
Sanchez-Valdes et al. have prepared multilayer films of polyethylene and AgNPs and evaluated their
antimicrobial activity towards Pseudomonas oleovorans and Aspergillus niger [95]. The authors showed
that the release of the Ag+ ions, and therefore the efficacy of this system, was dependent on the size
of the AgNPs. Other authors have focused their attention on the modification of the nanocomposite
surface, at the nanometer level, by combining the effects of oxygen plasma treatment and silver
nanoparticles on the poly(lactic-co-glycolic acid) (PLGA) polymer matrix [96]. In this study, PLGA
nanocomposite films were produced by solvent casting with 1 wt% and 7 wt% of AgNPs. The PLGA
(used as a control) and PLGA/Ag nanocomposite surfaces were then treated with oxygen plasma.
Antibacterial tests were performed using E. coli and S. aureus. The plasma-treated PLGA/Ag+ system
showed the best bactericidal effect in comparison to untreated PLGA/Ag+ or oxygen plasma-treated
PLGA matrix for both strains [96].
A different approach to prepare antibacterial coatings has been described by Taheri et al. where
AgNPs were encapsulated into a phospholipid bilayer and their surface immobilised to a functional
plasma polymer for application on medical devices such as catheters and wound dressings. The
antibacterial efficacy of the coatings was evaluated against S. aureus, S.epidermidis and P. aeruginosa.
The innate immune response was studied in culture of primary bone marrow-derived macrophages
(BMDM) and the potential cytotoxicity was assessed in culture of primary human fibroblasts. The
authors also observed a reduced expression of pro-inflammatory cytokines from BMDM which
suggested a reduced inflammatory response. The prepared coatings were able to reduce the growth of
S.aureus and P. aeruginosa by 70% and 80%, respectively, while colonization by S. epidermidis was almost
completely inhibited.
Studies have also moved towards the inclusion of additional materials to the AgNPs-polymer
containing systems. An example is the incorporation of growth factors (bone morphology protein-2,
BMP-2) and AgNPs into hydroxyapatite (HA) coatings on metallic implant surfaces for enhancing
osteo-inductivity and antibacterial properties. In this complex system, BMP-2 and AgNPs containing
HA coating were prepared on titanium (Ti) surfaces by electrochemical deposition (ED). In addition,
chitosan (CS) was used as a stabilising agent for the generation of the AgNPs, and simultaneously
reduced their toxicity. A schematic representation of this system is shown in Figure 7. Results of
antibacterial tests indicated that the CS/Ag/HA coatings have high antibacterial properties against both
S. epidermidis and E. coli. Additionally, bone marrow stromal cells (BMSCs) culture results indicated
that the BMP/CS/Ag/HA coatings have good osteoinductivity and promote the differentiation of
BMSCs. Implantation of Ti bars with BMP/CS/Ag/HA coatings into the femur of rabbits showed that
BMP/CS/Ag/HA coatings favour bone formation in vivo. Other studies can be found in the literature
reporting the inclusion of other biological or synthetic compounds into the AgNPs-polymers systems
such as bovine serum albumin and tiopronin.
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4.7.2. Nanofiber Systems Containing Silver Nanoparticles
The development of hybrid organic–metallic systems containing AgNPs embedded in nanofibers
has gained increasing interest due to the dual benefits of each individual system. Due to their high
surface-to-volume ratio, polymeric nanofibers can provide a larger number of reaction sites and higher
permeability. By embedding AgNPs into polymer nanofiber matrices, the composites are promising
candidates for scaffolding biomaterials with antimicrobial properties [85].
Nanofibers are mostly prepared by electrospinning. Either in combination with other polymers,
or on its own, biodegradable polymers such as PLGA, poly-caprolactone (PCL) and chitosan can be
electrospun and further functionalised to achieve the desired antibacterial properties [86]. Other studies
reported the one-step fabrication of silver nanoparticles embedded into poly(2-(tert-butylaminoethyl)
methacrylate) (PTBAM) nanofibers by radical-mediated dispersion polymerization. PTBAM is a
cationic polymer, which may increase the antimicrobial properties of the nanofibers loaded with AgNPs
against Gram-negative E. coli and Gram-positive S. aureus [98].
A few interesting studies have used bacterial cellulose functionalized with AgNPs for
wound-healing treatment [98,99]. Bacterial-derived cellulose, commonly known as bacterial cellulose
(BC), is produced by the fermentation of Gram-negative bacterium Acetobacter xylinum, which can
produce high aspect ratio nanofibers, with three-dimensional (3D) porous networks Authors showed
that AgNPs sized from 5 to 12 nm, with narrow size distribution, were successfully deposited on the
BC matrix. The studies showed a slow release of the AgNPs from the BC matrix, with the antibacterial
effect lasting after 7 days.
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4.7.3. Hydrogels Containing Silver Nanoparticles
Hydrogel-based dressings containing antimicrobial components have seen an increase in research
activity in wound-care applications. Boonkaew B. et al. have prepared 2-acrylamido-2-methylpropane
sulfonic acid sodium salt hydrogels containing AgNPs via ultraviolet radiation [100]. None of the
hydrogels were found to be toxic to any of the tested cell lines. The measurement of cumulative release
of silver indicated that 70–82% of silver was released within 72 h. The antibacterial activities against
Gram-positive S. aureus showed a log reduction >3 after 6 h of treatment. In the case of Gram-negative
P. aeruginosa, the results showed faster inhibition as the log reduction was >3 within 3 h. The fact that
Gram-positive bacteria are less susceptible to silver ions than Gram-negative bacteria could be related
to a) the fact that the cell wall of Gram-positive bacteria is thicker than that of Gram negative bacteria;
b) silver may get trapped by the negative charge of the peptidoglycan cell wall.
Hydrogel based wound dressing membranes have been developed using a combination of the
following polymers, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), agar and carboxymethyl
cellulose (CMC) [101]. Silver ions were dispersed in the polymer matrix and its reduction with
formation of a hydrogel and AgNPs was performed using gamma irradiation. In vitro and in vivo
results showed increased cicatrisation with the presence of large quantity of fibroblasts being detected
with little formation of collagen. Other studies explore the possibility of generating photo-activated in
situ poly (ethylene glycol) diacrylate (PEGDA) and PVP hydrogel composite containing AgNPs with
sustained anti-fouling/anti-bacterial activities [102]. The authors showed that the in situ method is
more effective than the two-step method since a) there is minimal gel softening; b) less dispersal of
nanoparticles; and c) lower concentration of metallic nanoparticles is needed, which reduces toxicity
to cells. The ability of the AgNPs-hydrogel composite to control bacterial growth was evaluated by
measuring bacterial growth rates in media immersed with the composite. The AgNP-PEGDA-PVP gel
composite limited the bacterial growth even at the silver concentration of 0.2 mM. At a concentration
of 10 mM, the system was able to inhibit bacterial growth over 5 days.
4.7.4. Inclusion of Other Metal Nanoparticles
Other metal particles are also known for their antimicrobial activity, although they are relatively
less studied than silver. Gold NPs (AuNPs) have exploited their unique chemical and physical
properties for transporting and unloading pharmaceutical compounds. The gold core is essentially
inert and non-toxic when compared to AgNPs [103]. Furthermore, AuNPs are chemically stable and
allow easy surface functionalization [104]. One of the most attractive modifications is the coating of
AuNPs with biocompatible polymers such as PEG and chitosan, which by creating composites with a
modulate mechanical strength can improve their features as biomedical scaffolds [105,106].
Chitosan-AuNPs nanocomposites prepared by a solvent evaporation method showed high
antibacterial activity and simultaneously low cytotoxicity. It has been shown that the molecular weight
(Mw) and deacetylation degree of chitosan influences the size of the AuNPs formed. The resulting
nanocomposites demonstrated total bactericidal effect against two biofilm forming antimicrobial
resistant strains (S. aureus and P. aeruginosa) [107]. Other studies showed that chitosan- AuNPs systems
have concentration-dependent bactericidal ability without damaging human macrophages in an
in vitro infection model, causing bacterial wall damage as the killing mechanism [108].
Hybrid PEG-AuNPs nanocomplexes can be effectively bio-conjugated with the enzymes or
proteins [109,110]. More recently, a study has demonstrated that engineered hybrid PEG-AuNPs
covalently conjugated with a peptide called innate defense regulator (IDR)-1018 showed both
bactericidal and antibiofilm properties at micromolar concentration bacteria [111]. The surface
of the AuNPs can also be modified with molecules that serve as the main structural components of
β-lactam antimicrobials, such as 6-aminopenicillanic acid (6-APA) [112]. The APA-modified AuNPs
were electrospun with PCL/gelatin to obtain biocompatible antibacterial wound dressings. The
antibacterial activity in skin wound healing by a dorsal wound model of a rat exposed to E. coli, MDR
E. coli, P. aeruginosa and MDR P. aeruginosa was investigated. The results showed that wounds treated
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with Au-APA electrospun nanofibers had better wound-healing ability than gauze and PCL/gelatin
nanofibers even against MDR bacterial wound infection.
Copper nanoparticles (CuNPs) have been shown to have excellent antimicrobial properties. This
could be due to an increased concentration of copper inside the cell which causes oxidative stress and
forms hydrogen peroxide. Furthermore, excess copper causes a decrease of the membrane integrity of
microorganisms, leading to the loss of vital nutritional cell elements, causing desiccation and eventually
cell death [113]. Incorporation of CuNPs into medical grade polymers has also been described. CuNPs
incorporated into polyurethane and silicone polymers displayed potent antibacterial activity against
methicillin-resistant S. aureus and E. coli within 6 h [114].
Lu et al. added CuNPs to the mixture of anionic carboxymethyl chitosan (CMC) and alginate (Alg)
polymers [115]. The authors found that the CMC/Alg/Cu scaffolds showed significantly improved
capabilities of osteogenesis and killing clinical bacteria compared to CMC/Alg scaffolds fabricated
by the same procedure but without adding CuNPs. Furthermore, in vivo studies demonstrated that
CMC/Alg/Cu scaffolds could induce the formation of vascularized new bone tissue in 4 weeks while
avoiding clinical bacterial infection even when the implantation sites were challenged with clinically
relevant S. aureus bacteria.
4.7.5. Inclusion of Titanium Dioxide and Zinc Oxide
Titanium-based alloys as biomaterials have many advantages due to their lower modulus, intensive
corrosion resistance and superior biocompatibility [116]. Furthermore, titanium dioxide (TiO2) is a
chemically stable and inert material, and when illuminated, can continuously exert antimicrobial
effects by the generation of superoxide and hydroxyl radicals [117]. Similarly to what has been
reported for other metal NPs, TiO2 nanoparticles (TiO2NPs) have also been incorporated into polymeric
systems by different techniques and their antibacterial properties demonstrated against a variety of
microorganisms. Chitosan, PLA and PLGA remain the most widely used polymers for this purpose.
Fonseca et al. prepared PLA composites containing TiO2NPs, with a diameter of 10 nm and
homogeneously dispersed in the polymer matrix. The PLA nanocomposites containing 8 wt% of
TiO2NPs when irradiated with light and ultraviolet-A (UVA), showed a reduction of ~94.3% and 99.9%
against E. coli and Aspergillus fumigatus, respectively. Toniatto, T.V. and his co-authors also used PLA
polymer but in the fiber shape. They prepared electrospun PLA fibers with high loadings of TiO2NPs
(1–5 wt%), which possessed bactericidal activity against S. aureus, however which showed no in vitro
cytotoxicity using a L929 cell line [118]. Furthermore, studies have also evaluated the feasibility of
PLGA-TiO2NPs composite biofilms under UV light irradiation, on wound healing in vitro, human
keratinocytes (HaCaTs), fibroblasts (L929s), and bovine carotid artery endothelial cells (BECs) [87].
These results showed that the biofilms for artificial dressing applications, containing 10% TiO2NPs,
were effective against E. coli and S. aureus and had a good biocompatibility on HaCaTs and L929s,
however they had some cytotoxic effects on BECs.
An interesting study of porous scaffolds of collagen and chitosan-containing TiO2NPs were
evaluated as tissue engineering for wound repair. The collagen–chitosan composite scaffolds with
various concentrations of TiO2NPs were prepared by freeze-drying technique. The scaffolds showed
an inhibitory effect on S. aureus, good permeability and it may provide a humid environment
for wound repairing [119]. Chitosan has been used in other studies combined with TiO2NPs for
antibacterial applications [120]. Other binary polymer combinations containing poly(ether ether
ketone) (PEEK)/poly(ether imide) (PEI) blends reinforced with bioactive TiO2NPs were fabricated via
ultrasonication followed by melt-blending [121]. The nanocomposites showed significant antibacterial
properties against human pathogenic bacteria with and without UV illumination, and the effect on
S. aureus was systematically stronger than that on E. coli.
Zinc oxide (ZnO) nanoparticles (ZnONPs) have been widely investigated thanks to its
multifunctional properties coupled with the ease of preparing various morphologies, such as
nanowires, nanorods, and nanoparticles [122]. Three-dimensional and interconnected porous granules
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of nanostructured hydroxyapatite (nanoHA) incorporated with different amounts of ZnONPs have
been prepared by a simple polymer sponge replication method [123]. Granules loaded with 2%
ZnONPs showed a strong antibacterial effect against S. aureus and S. epidermidis. In vivo studies
used nanoHA porous granules with and without ZnONPs implanted into the subcutaneous tissue in
rats and their inflammatory response after 3, 7 and 30 days was examined. The results showed the
potential of these systems in reducing bacterial activity in vitro and in vivo, with a low cell growth
inhibition in vitro and no differences in the connective tissue growth and inflammatory response
in vivo. Sustained release preparations of polymers containing ZnONPs have been described by the
formation of crosslinked polymer networks with ZnNPs in the form of hydrogels [124].
4.8. Dendrimers
Dendrimers are a class of molecule and the word is derived from dendron which means tree
for their characteristic branch-like appearances (Figure 8). The most common dendrimers used for
biological applications are based on polyamidoamines (PAMAM) and polypropylene imine (PPI),
(Figure 9). Dendrimers are synthesized from the core and develop into a globular structure with
the size between 2–5 nm. The core structure provides attachment of the dendrons and each section
represents a generation (G1, G2, G3) (Figure 8). The higher generation the dendrimer is built of, the
more branched and exposed number of end groups are available for conjugation with other molecules
including small molecule antibiotics [125]. Dendrimers’ chemical branches can be tailored according
to the solubility and degradability to enhance biological activity of interest [126].
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Dendrimers can demonstrate its own antibacterial activities through interaction with the bacterial
lipid bilayer and causes destablisation of the bacterial structure [127]. Mofrad et al., 2018 demonstrated
the efficacy of G3-poly-amidoamine dendrimer (G3-PAD) against seven species of Gram-negative and
-positive bacteria. Interestingly, the highest sensitivity was observed for Salmonella species with the
least susceptibility were observed in Klebsiella species. The author suggested differences in the bacterial
membrane composition contributed to the strong barriers against the entrance of dendrimers inside the
bacteria [128]. Additionally, Pires et al. 2015 demonstrated effective antimicrobial activities of peptide
dendrimer, G3KL against multidrug resistant Acinetobactor baumanii and P. aeruginosa [129]. These two
examples are only selected research on dendrimers’ antibacterial activities and readers are invited to
refer more on related information as provided by [125]. Due to the multi- functional group within
dendrimers, the molecules can also be conjugated with existing antibiotics to potentiate their activities.
Interestingly, stimulus-controlled antibiotic released from the dendrimer can be achieved by specific
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triggers, for example, light, pH or temperature. Some examples of the successful functionalization of
antibiotics are summarized in Table 4.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  23 of 35 
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Table 4. Examples of dendrimers conjugated with antibiotics.
Dendrimers AntibioticsConjugates Pathogens Tested
Mechanism of
Antibiotic Release References
Polyamidoamines
(PAMAM) Ciprofloxacin E. coli Light-active release [130]
PAMAM Vancomycin S. aureus Temperature-activerelease [131]
PAMAM Vancomycin S. aureus NA [132]
PAMAM Erythromycin S. aureus Hydrolysis of theester linkage [133]
Polypropylene imine
(PPI)-modified maltose Amoxicillin
E. coli and
P. aeruginosa NA [134]
PPI Ceftazidime P. aeruginosa pH-active release [135]
Polyesters Fusidic acid S. aureus Water-activerelease [136]
Carbohydrate-glycopeptide Tobramycin P. aeruginosa Temperature-activerelease [137]
4.9. Polymer-Based Guanidine
Guanidine-like compounds have been investigated for the past three decades and have given
benefit in diverse medicinal field (Figure 10a) [138,139]. Guanidine can be found in natural terrestrial
and marine environments such as microorganisms, plants and invertebrates [140]. Guanidine displays
cationic properties and this allows for interaction with the anionic counterpart. The side chain
diversity of guanidine allows for further development of guanidine scaffold for different therapeutic
purposes [141]. Compounds containing guanidine have attracted interest and have been successfully
applied as therapeutics for the central nervous system, anti-inflammatory agents, anti-thrombotic agents,
anti-diabetic agents and antimicrobial agents [138]. One of the most commonly used antimicrobial
polymers is polyhexamethylene biguanide (PHMB) or also known as polyhexanide (Figure 11). PHMB
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is synthesized by oligomirazation of guanidine salts and hexamethylenediaemine [141]. PHMB has
been widely used in domestic applications, as an antiseptic in medicine, and in the food industry.
PHMB applications include impregnation of wound dressings, water treatment, mouthwash and
disinfection in contact lenses [142–144].
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PHMB is a potent topical antimicrobial against Gram-positive and Gram-negative bacteria, fungi,
parasites and viruses [144–148]. PHMB antimicrobial activities involve the interaction of biguanide
groups with the cytoplasmic membrane, lipopolysaccharide and peptidoglycan of the bacterial cell wall.
This binding is believed to displace the divalent cation Ca2+ causing membrane destabilization and
cellular leakages [145]. Simultaneously, the hexamethylene segment can interact with phospholipids
on the membrane, causing a phase separation that disturbs random distribution of lipids, further
destabilizing the membrane structure. Furthermore, Chindera et al. demonstrated that PHMB enters
bacteria cells and this leads to chromosome condensation [148]. Therefore, PHMB may have at least
two mechanisms of action, and this may help to explain why acquired antimicrobial resistance to
PHMB has not yet been reported, despite being used in the clinic and domestic application for the past
40 years.
PHMB has also been reported to enter mammalian cells and kill intracellular bacteria (MRSA)
and parasites (Leishmania spp.) at low dosage (Figure 11) [22,149]. Additionally, due to the cationic
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nature of the molecules, PHMB is able to form nanoparticles with other small antibiotic molecules thus
potentiate its antibacterial activities [20,148,149]. PHMB is considered less toxic towards mammalian
cells compared to other compounds in its class. Muller and Kramer, 2008 compared the cellular
cytotoxicity of PHMB and other commonly used antiseptics in the clinic and found that PHMB has a
higher biocompatibility index towards mammalian cells than other antiseptics tested [150].
5. Challenges in Bringing Antimicrobial Polymers into Clinics
Now comes the main question as to whether bench to bedside translation of these antimicrobial
polymers would come into reality or remains as the research output and ends only in the publication
repository. Before choosing to embark to the clinical journey, it is mandatory for the researcher to
assess the in-vitro and in-vivo toxicity, biocompatibility, evaluation of the cell viability, biodistribution,
immunogenicity in order to reach the go/no go decision. Mignani et al. provide an excellent guideline
on the translational requirements for dendrimers and nanoparticles to move the compounds towards
the investigational new drug (IND) application, which is the evaluation of the safe profile before
initiating clinical trials, the first essential step to entering the clinic phase [139]. We believe the guideline
is also applicable for antimicrobial polymers and readers are invited to refer to this excellent review for
comprehensive information [139].
Once the researcher establish the risk/benefit ratio, it is a wise decision to understand from the
early stages the potential route of application for the compound. If the compound shows good efficacy
and has potential for development as oral drugs, the researcher must understand what are the suitable
requirements for the oral route, and understand the Lipinsky rule of five could be a good start [151].
However, based on the history of antibiotics development and commercialisation, antibiotics generally
do not obey these rules [152]. If the compound turns out to be less likely to be developed in the oral
route, other routes of administration can be an alternative, for example, topical. The guideline for
development of a topical product are extensively reviewed by Chang et al. 2015 [153].
6. Conclusions and Future Considerations
We are living in an era where the globe is increasingly connected with highly mobile populations,
moving easily between different countries, which is a compounding factor in the global AMR
challenge [154]. Indeed, in 2016 at a UN General Assembly, countries worldwide affirmed their
commitment to develop national action plans based on the WHO Global Action Plan for Antibiotic
Resistance (2015) [2]. In principle, the plan aims to ensure “treatment and prevention of infectious
diseases with quality-assured, safe and effective medicines”. A key relevant objective within the
proposed WHO action plan is to strengthen knowledge through surveillance and research.
In order to provide a tangible new medicine as part of the solution for the increasing AMR problem,
we propose that a network based multidisciplinary approach is vital. A continuous collaboration
between chemists, microbiologists and clinicians is paramount to further develop and translate
promising antimicrobial polymers for use in the clinic. One such polymer group to highlight is
those containing guanidine; specifically, polyhexamethylene biguanide (PHMB) and its nanoparticle
constructs, and this has been used for topical/local application. Despite PHMB being in use both for
clinical and domestic purposes for over 40 years, there are no reports of resistance to date. Lack of
acquired resistance is likely due to multimodal antimicrobial [145,148]. PHMB is particularly interesting
for exhibiting broad spectrum activity against intracellular bacteria and parasites in nanoparticle form.
Of note, PHMB demonstrates antimicrobial effects at low concentrations and has been shown to have
lower toxicity than other agents of its class [20,150,155]. Future studies exploring the delivery options
for PHMB, novel formulations with small molecule antibiotics, and interactions with ESKAPE isolates
are required.
Clearly, going forward, the success of any existing, novel or reformulated antimicrobial of the
polymer class must (i) be effective at controlling infection, (ii) exhibit low toxicity towards the host
and (iii) ideally harness a multimodal arsenal of antimicrobial activity in order to provide long-term
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sustainability. Finally, we call on national research funding agencies to continue their commitment
to the global AMR challenge. Strategic, allocated funding will play a key role in supporting the
development and in vivo application of novel polymeric systems to treat resistant microbial infections
that, currently, available therapeutics are failing to treat.
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